The stock of Travere Therapeutics Inc (TVTX) has gone down by -0.14% for the week, with a 0.10% rise in the past month and a 20.31% rise in the past quarter. The volatility ratio for the week is 3.92%, and the volatility levels for the past 30 days are 5.21% for TVTX. The simple moving average for the past 20 days is 3.91% for TVTX’s stock, with a 34.62% simple moving average for the past 200 days.
Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?
The 36-month beta value for TVTX is at 0.78. Analysts have varying views on the stock, with 11 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for TVTX is 87.41M, and currently, shorts hold a 12.81% of that float. The average trading volume for TVTX on March 26, 2025 was 1.59M shares.
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX)’s stock price has gone decline by -1.62 in comparison to its previous close of 21.01, however, the company has experienced a -0.14% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-03-17 that sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Additionally, the FDA notified the Company that REMS monitoring for embryo-fetal toxicity is no longer necessary; the Company plans to submit an amendment to the REMS sNDA currently under review for modification of liver monitoring SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The submission is supported by results from the Phase 3 DUPLEX Study and the Phase 2 DUET Study, two of the largest head-to-head interventional studies conducted to date in adult and pediatric patients with FSGS.
Analysts’ Opinion of TVTX
Wells Fargo, on the other hand, stated in their research note that they expect to see TVTX reach a price target of $27, previously predicting the price at $9. The rating they have provided for TVTX stocks is “Overweight” according to the report published on October 21st, 2024.
TVTX Trading at 0.50% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.27% of loss for the given period.
Volatility was left at 5.21%, however, over the last 30 days, the volatility rate increased by 3.92%, as shares sank -1.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.19% upper at present.
During the last 5 trading sessions, TVTX fell by -0.14%, which changed the moving average for the period of 200-days by +185.89% in comparison to the 20-day moving average, which settled at $19.89. In addition, Travere Therapeutics Inc saw 18.66% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVTX starting from ROTE WILLIAM E., who sale 5,200 shares at the price of $23.53 back on Feb 12 ’25. After this action, ROTE WILLIAM E. now owns 98,519 shares of Travere Therapeutics Inc, valued at $122,356 using the latest closing price.
REED ELIZABETH E, the SVP, GC & CORPORATE SECRETARY of Travere Therapeutics Inc, sale 8,000 shares at $23.53 during a trade that took place back on Feb 12 ’25, which means that REED ELIZABETH E is holding 89,482 shares at $188,240 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -1.38 for the present operating margin
- 0.92 for the gross margin
The net margin for Travere Therapeutics Inc stands at -1.38. The total capital return value is set at -0.82. Equity return is now at value -246.75, with -46.37 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.87 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 6.8. The interest coverage ratio of the stock is -28.78.
Currently, EBITDA for the company is -265.77 million with net debt to EBITDA at -1.29. When we switch over and look at the enterprise to sales, we see a ratio of 9.31. The receivables turnover for the company is 8.6for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.08.
Conclusion
In conclusion, Travere Therapeutics Inc (TVTX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
